Baclofen
- Generic Name
- Baclofen
- Brand Names
- Fleqsuvy, Gablofen, Kemstro, Lioresal, Lyvispah, Ozobax
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClNO2
- CAS Number
- 1134-47-0
- Unique Ingredient Identifier
- H789N3FKE8
- Background
Baclofen is a gamma-aminobutyric acid (GABA) agonist used as a skeletal muscle relaxant. Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FD...
- Indication
Oral baclofen is indicated for the treatment of spasticity resulting from multiple sclerosis and is particularly useful for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. It may also be used to treat patients with spinal cord injuries and other spinal cord diseases. Baclofen should not be used to treat skeletal muscle spasms...
- Associated Conditions
- Alcohol Dependency, Severe Spasticity, Spasticity, Flexor spasm, Severe cerebral origin Spasticity, Severe spinal cord origin Spasticity
- Associated Therapies
- -
Effect of Baclofen on Marijuana Withdrawal and Relapse
- Conditions
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 13
- Registration Number
- NCT00373295
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00320047
- Locations
- 🇺🇸
Eating Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States
Baclofen Effects on Smoking Urge and Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 41
- Registration Number
- NCT00257894
- Locations
- 🇺🇸
VA Medical Center, Providence, Providence, Rhode Island, United States
Does Reducing Spasticity Permit an Increase in Strength?
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT00255073
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00139789
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
Baclofen for the Treatment of Cocaine Dependence - 1
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 160
- Registration Number
- NCT00082485
- Locations
- 🇺🇸
San Francisco General Hosptial, San Francisco, California, United States
🇺🇸Denver VA Medical Center, Denver, Colorado, United States
🇺🇸South TX VA Health Care System, San Antonio, Texas, United States
Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT00000303
- Locations
- 🇺🇸
Friends Research Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.